CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma's earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia. It also evaluates its pipeline candidate paclitaxel poliglumex, which targets solid tumors.

TypePublic
HQSeattle, US
Founded1992
Size (employees)100 (est)
Websitectibiopharma.com
CTI BioPharma was founded in 1992 and is headquartered in Seattle, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

CTI BioPharma Office Locations

CTI BioPharma has an office in Seattle
Seattle, US (HQ)
600 3101 Western Ave
Show all (1)
Report incorrect company information

CTI BioPharma Financials and Metrics

CTI BioPharma Revenue

CTI BioPharma's revenue was reported to be $25.15 m in FY, 2017
USD

Revenue (Q2, 2018)

11.1m

Net income (Q2, 2018)

(15.4m)

EBIT (Q2, 2018)

(18.3m)

Market capitalization (15-Oct-2018)

113.1m

Closing stock price (15-Oct-2018)

2.0

Cash (30-Jun-2018)

65.4m

EV

50.3m
CTI BioPharma's current market capitalization is $113.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

34.7m60.1m16.1m57.4m25.1m

Revenue growth, %

73%(73%)256%

Cost of goods sold

137.0k895.0k1.9m1.4m

Gross profit

34.5m59.2m14.2m56.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

362.0k1.4m1.3m39.5m2.7m1.1m964.0k36.5m7.4m4.4m754.0k22.2m10.5m11.1m

General and administrative expense

8.5m16.8m13.8m12.6m12.3m12.6m13.7m11.3m9.6m15.2m10.7m8.0m5.4m10.3m

R&D expense

7.2m12.2m14.0m16.5m17.5m19.3m18.4m20.8m16.7m17.7m9.3m8.9m9.7m18.8m

Operating expense total

15.9m29.1m28.0m32.1m30.2m32.1m32.9m32.3m26.4m33.1m20.1m17.0m15.1m29.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

71.6m70.9m128.2m44.0m27.2m

Accounts Receivable

235.0k2.0m282.0k378.0k4.0k

Inventories

3.6m3.4m3.7m1.5m550.0k

Current Assets

80.5m80.5m135.0m55.8m46.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

27.2m50.6m33.2m29.9m44.4m54.9m46.4m104.6m76.7m61.6m33.3m74.7m104.6m65.4m

Accounts Receivable

540.0k503.0k613.0k1.2m1.3m880.0k422.0k666.0k559.0k620.0k311.0k480.0k

Inventories

3.7m5.0m5.0m4.5m3.6m3.6m2.6m2.9m2.6m2.6m1.5m1.5m564.0k

Current Assets

33.7m59.9m42.3m55.9m53.5m63.9m53.3m113.9m88.9m67.9m36.8m78.4m107.8m95.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(43.5m)(94.2m)(120.8m)(53.0m)

Depreciation and Amortization

1.6m1.1m990.0k831.0k717.0k

Inventories

4.5m46.0k(402.0k)567.0k1.1m

Accounts Payable

(5.8m)1.5m4.4m(3.0m)(4.7m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(29.0m)(27.4m)(28.6m)(32.6m)(32.6m)3.3m(19.8m)(29.2m)(19.8m)

Depreciation and Amortization

152.0k302.0k

Inventories

5.0m4.5m3.6m3.6m

Accounts Payable

6.4m6.3m10.3m11.2m13.4m17.7m14.0m13.7m11.9m(419.0k)1.1m
USDY, 2018

EV/EBIT

-2.7 x

EV/CFO

-3.3 x

Financial Leverage

1.6 x
Show all financial metrics

CTI BioPharma Operating Metrics

FY, 2016

Phase III Trials Products

2
Show all operating metrics
Report incorrect company information

CTI BioPharma Online and Social Media Presence

Embed Graph
Report incorrect company information

CTI BioPharma News and Updates

CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

SEATTLE, Sept. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay Hotel. Presentation details: Event:...
Report incorrect company information

CTI BioPharma Company Life and Culture

Report incorrect company information